Merger Notification - Announcement according to § 10 Cartel Act
Raiffeisen Continuum GmbH & Co KG; HOMEOCUR Dr. Leisser GmbH; St. Martin-Apotheke Mag. Christoph Splichal KG; SPLIPHARM Arzneiwaren HandelsgmbH; Doropharm k.s
BWB/Z-6274
On 12.05.2023 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
RAICONT-APO-1.0 Beteiligung GmbH Raiffeisen Continuum GmbH & Co KG (Austria), a subsidiary of Raiffeisen Bank International AG (Austria), and "HOMEOCUR" Dr. Leisser GmbH (Austria) intend to acquire more than 25% each of the shares in a limited partnership yet to be founded, into which all assets of St. Martin-Apotheke Mag. Christoph Splichal KG (Vienna / Austria) will be contributed.
At the same time, Raiffeisen Continuum Holding GmbH & Co KG (indirectly via SPLIPHARM Arzneiwaren HandelsgmbH (Austria)) will acquire 35% of the shares in and control over Doropharm Health, sro (Slovakia), into which all assets of Doropharm, k.s. (Slovakia) will be contributed.
The Proposed Transaction concerns a pharmacy and the wholesale of pharmaceuticals.
Affected business areas: Dispensing chemist in specialised stores; Whole-sale of pharmaceutical goods
Industry sector: G - Handel; Instandhaltung und Reparatur von Kraftfahrzeugen
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 09.06.2023.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 10.06.2023 .